Cargando…

Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma

Background: This systematic review and meta-analysis aims to provide comparative and quantitative data about immune checkpoint inhibitor (IMM) and targeted therapy (TAR) in this work. Methods: A literature search was performed with PubMed, Embase, PMC database, and Web of Science databases to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Minliang, Wang, Yuchong, Xu, Yalong, Zhu, Ji, Lv, Chuan, Sun, Mengyan, Guo, Rui, Xia, Yu, Zhang, Wei, Xue, Chunyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856565/ https://www.ncbi.nlm.nih.gov/pubmed/31762821 http://dx.doi.org/10.7150/jca.32638

Ejemplares similares

Comparison of Proangiogenic Effects of Adipose-Derived Stem Cells and Foreskin Fibroblast Exosomes on Artificial Dermis Prefabricated Flaps
por: Xiong, Jiachao, et al.
Publicado: (2020)

Adipose-Derived Stem Cells Exosomes Improve Fat Graft Survival by Promoting Prolipogenetic Abilities through Wnt/β-Catenin Pathway
por: Chen, Kexin, et al.
Publicado: (2022)

Gene expression profile analysis on different stages of hypertrophic scarring in a rabbit ear model
por: Zhu, Ji, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy
por: Wu, Minliang, et al.
Publicado: (2019)

Metformin promotes angiogenesis by enhancing VEGFa secretion by adipose-derived stem cells via the autophagy pathway
por: Tao, Zihan, et al.
Publicado: (2023)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
por: Olbryt, Magdalena, et al.
Publicado: (2020)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma
por: Melin, Audrey, et al.
Publicado: (2022)

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
por: L’Orphelin, Jean-Matthieu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
por: Morante, Marta, et al.
Publicado: (2022)

Type 1 diabetes induced by immune checkpoint inhibitors
por: Zhang, Rui, et al.
Publicado: (2020)

Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population
por: Wei, Khor Zhong, et al.
Publicado: (2019)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
por: Marco, Tucci, et al.
Publicado: (2019)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
por: Vukadin, Sonja, et al.
Publicado: (2021)

Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
por: Jang, Se Ryeong, et al.
Publicado: (2021)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
por: Ferraresi, Virginia, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h31umj2t6nqap47e7st9i4m81t